計量生物学
Online ISSN : 2185-6494
Print ISSN : 0918-4430
ISSN-L : 0918-4430
第7回計量生物セミナー臨床の部プログラム
Population PK/PD解析を用いた評価法
朝野 芳郎
著者情報
ジャーナル フリー

2003 年 24 巻 Special_Issue 号 p. S85-S98

詳細
抄録

The ICH E5 is currently focusing on the effective utilization of overseas data as the bridging data package. In consideration of the bridging strategy, we have to provide the simlarities in pharmacokinetic (PK) and pharmacodynamic (PD) profiles between the new region’s population and the original region's. These profiles are correlated to each other.
The currently recommended bridging strategy is the following:
In the first step, we have to evaluate the PK profile of the new region to judge the necessity of dose adjustment due to the ethnic differences in PK.
Secondly, a dose-response study is usually conducted as bridging study, in which we have to evaluate PD profiles which include efficacy and safety. It is generally useful to incorporate the relationship among PK profile, disease progression and drug response into the proper population PK/PD model in bridging studies.
Demonstrating similarity of bridging studies is diffcult because the obtained information from patients is often incomplete and biased. In order to confirm effcacy and to demonstrate similarity between ethnic groups in clinical studies, effcacy should be clinically evaluated from multiple perspectives through refined analysis based on a model, which includes mechanism-based population PK/PD model.
Construction and evaluation of the mechanistic PK/PD model in effcacy and safety may be able to explain the ethnic similarity, even though the external circumstances are different.

著者関連情報
© 2003 日本計量生物学会
前の記事 次の記事
feedback
Top